Literature DB >> 21951597

The role of antimalarial treatment in the elimination of malaria.

R D Gosling1, L Okell, J Mosha, D Chandramohan.   

Abstract

With declining transmission of malaria in several regions of the world and renewed interest in the elimination of malaria, strategies for malaria control using antimalarial drugs are being revisited. Drug-based strategies to reduce transmission of malaria need to target the asymptomatic carriers of infection. Drugs that are effective against gametocytes are few in number, but it may be possible to reduce gametocyte production by killing the asexual stages, for which more drugs are available. Drugs for use in large-scale programmes must be safe and tolerable. Strategies include improving access to treatment for malaria with an efficacious drug, intermittent-treatment programmes, and mass drug administration, with and without screening for malaria. Recent proposals have targeted high-risk groups for interventions. None of the strategies has been rigorously tested with appropriate control groups for comparison. Because of the lack of field evidence, modelling has been used. Models have shown, first, that for long-lasting effects, drug administration programmes should be linked with vector control, and second, that if elimination is the aim, programmes are likely to be more successful when applied to smaller populations of a few thousand or less. In order to sustain the gains following the scaling up of vector control and use of artemisinin combination therapies (ACTs), strategies that use antimalarials effectively need to be devised and evidence generated for the most cost-efficient way forward.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21951597     DOI: 10.1111/j.1469-0691.2011.03660.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  31 in total

1.  Large-scale Artemisinin-Piperaquine Mass Drug Administration With or Without Primaquine Dramatically Reduces Malaria in a Highly Endemic Region of Africa.

Authors:  Changsheng Deng; Bo Huang; Qi Wang; Wanting Wu; Shaoqin Zheng; Hongying Zhang; Di Li; Danghong Feng; Guoming Li; Linlu Xue; Tao Yang; Fei Tuo; Fouad Mohadji; Xin-Zhuan Su; Qin Xu; Zhibing Wu; Li Lin; Jiuyao Zhou; Hong Yan; Affane Bacar; Kamal Said Abdallah; Rachadi A Kéké; Ahamada Msa Mliva; Moussa Mohamed; Xinhua Wang; Shiguang Huang; Fatihou Oithik; Xiao-Bo Li; Fangli Lu; Michael P Fay; Xiao-Hong Liu; Thomas E Wellems; Jianping Song
Journal:  Clin Infect Dis       Date:  2018-11-13       Impact factor: 9.079

Review 2.  The interplay between drug resistance and fitness in malaria parasites.

Authors:  Philip J Rosenthal
Journal:  Mol Microbiol       Date:  2013-08-16       Impact factor: 3.501

3.  Impact of Intermittent Mass Testing and Treatment on Incidence of Malaria Infection in a High Transmission Area of Western Kenya.

Authors:  Meghna R Desai; Aaron M Samuels; Wycliffe Odongo; John Williamson; Nobert Awino Odero; Kephas Otieno; Ya Ping Shi; Stephen Patrick Kachur; Mary J Hamel; Simon Kariuki; Kim A Lindblade
Journal:  Am J Trop Med Hyg       Date:  2020-04-23       Impact factor: 2.345

4.  The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial.

Authors:  Joseph Okebe; Teun Bousema; Muna Affara; GianLuca DiTanna; Alice C Eziefula; Musa Jawara; Davis Nwakanma; Alfred Amambua-Ngwa; Jean-Pierre Van Geertruyden; Chris Drakeley; Umberto D'Alessandro
Journal:  Trials       Date:  2015-03-01       Impact factor: 2.279

5.  G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map.

Authors:  Rosalind E Howes; Frédéric B Piel; Anand P Patil; Oscar A Nyangiri; Peter W Gething; Mewahyu Dewi; Mariana M Hogg; Katherine E Battle; Carmencita D Padilla; J Kevin Baird; Simon I Hay
Journal:  PLoS Med       Date:  2012-11-13       Impact factor: 11.069

6.  Reactive case detection for malaria elimination: real-life experience from an ongoing program in Swaziland.

Authors:  Hugh J W Sturrock; Joe M Novotny; Simon Kunene; Sabelo Dlamini; Zulisile Zulu; Justin M Cohen; Michelle S Hsiang; Bryan Greenhouse; Roly D Gosling
Journal:  PLoS One       Date:  2013-05-20       Impact factor: 3.240

Review 7.  Malaria in infants aged less than six months - is it an area of unmet medical need?

Authors:  Umberto D'Alessandro; David Ubben; Kamal Hamed; Serign Jawo Ceesay; Joseph Okebe; Makie Taal; Eugene Kaman Lama; Moussa Keita; Lamine Koivogui; Alain Nahum; Kalifa Bojang; Aja Adam Jagne Sonko; Honorat Francis Lalya; Bernard Brabin
Journal:  Malar J       Date:  2012-12-02       Impact factor: 2.979

8.  Modelling the cost-effectiveness of mass screening and treatment for reducing Plasmodium falciparum malaria burden.

Authors:  Valerie Crowell; Olivier J T Briët; Diggory Hardy; Nakul Chitnis; Nicolas Maire; Aurelio Di Pasquale; Thomas A Smith
Journal:  Malar J       Date:  2013-01-03       Impact factor: 2.979

9.  A novel live-dead staining methodology to study malaria parasite viability.

Authors:  Erica M Pasini; Denise van den Ierssel; Henri J Vial; Clemens H M Kocken
Journal:  Malar J       Date:  2013-06-07       Impact factor: 2.979

Review 10.  Antimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR Network.

Authors:  Liwang Cui; Sungano Mharakurwa; Daouda Ndiaye; Pradipsinh K Rathod; Philip J Rosenthal
Journal:  Am J Trop Med Hyg       Date:  2015-08-10       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.